CHMP recommends that Rasilez remain on market with modified label: http://www.sec.gov/Archives/edgar/data/1114448/000110465912010805/a12-5346_16k.htm The decision is mostly academic, however, insofar as NVS has ceased nearly all promotion of the drug.